ArticleJTO clinical and research reports2023

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report.

Huihui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.